Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2019-10-29 Capital/Financing Update
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Dofinansowanie Projektu rozwijanego przez Bacteromic sp. o.o., spółkę zależną Scope Fluidics S.A - podpisanie umowy z The Executive Agency for Small and Medium-sized Enterprises (EASME). - Content ...
Capital/Financing Update Classification · 1% confidence The document text announces that a subsidiary of Scope Fluidics S.A. signed an agreement with The Executive Agency for Small and Medium-sized Enterprises (EASME) to receive funding of 1.927 million EUR from the SME Instrument under Horizon 2020. This funding relates to the continuation of development, clinical validation, and commercialization of the BacterOMIC system. This is a specific announcement regarding financing and fundraising activities for a project. This aligns best with the 'Capital/Financing Update' category (CAP), as it details the acquisition of significant external funding/grant money for development, which is a form of capital activity. It is not a general earnings release (ER), a full annual report (10-K), or a management discussion (MDA). Given the specific nature of securing a large grant/financing agreement, CAP is the most appropriate classification.
2019-10-29 Polish
Podpisanie umów o dofinansowanie ze środków unijnych projektów dotyczących uzyskania międzynarodowej ochrony patentowej wynalazków opracowanych dla systemu BacterOMIC - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board ('Zarząd') of Scope Fluidics S.A. regarding its subsidiary signing grant agreements ('umów o dofinansowanie') with the Polish Agency for Enterprise Development (PARP) for projects related to obtaining international patent protection. This concerns financing, grants, and intellectual property protection, which falls under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no better fit exists. Since the core subject is securing funding/grants for development and patent protection, 'Capital/Financing Update' (CAP) is the most appropriate specific category, as it relates to capital structure/funding activities, even if the funding is in the form of a grant. The document is short and appears to be the primary announcement itself, not a link to a larger report.
2019-10-28 Polish
Wybór przez PARP do dofinansowania projektu dotyczącego uzyskania międzynarodowej ochrony patentowej kartridża stosowanego w systemie PCR|ONE - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board ('Zarząd') of Scope Fluidics S.A. regarding a project undertaken by its subsidiary being selected for funding ('dofinansowania') by the Polish Agency for Enterprise Development ('PARP'). The content discusses securing funding (349,000 PLN) for international patent protection. This relates directly to financing activities, capital structure, or fundraising efforts for the company's operations and intellectual property. It is not an Annual Report (10-K), Earnings Release (ER), or Interim Report (IR). It is a specific announcement about securing funds for a project, which aligns best with 'Capital/Financing Update' (CAP). It is not a general regulatory filing (RNS) because a more specific category exists, nor is it a mere announcement of a report (RPA). The key indicators are 'dofinansowania' (funding/subsidy) and the context of securing funds for patent protection, which falls under financing activities.
2019-09-20 Polish
Aktualny stan rozwoju technologii systemu PCR|ONE oraz systemu BacterOMIC - Content (PL)
Environmental & Social Information Classification · 1% confidence The document details the results of internal verification tests conducted on two systems, PCR|ONE and BacterOMIC, focusing on detecting MRSA and testing antibiotic interactions. It provides detailed statistical results (sensitivity, specificity, true/false positives/negatives) from laboratory testing on bacterial strains and clinical swabs. This content is highly technical and relates to the performance and validation of diagnostic technology, which aligns best with reporting on internal testing or development progress. Since it is a detailed report on internal testing results rather than a general announcement of results (ER) or a formal regulatory audit report (AR), it fits the description of a technical or development update. Given the options, this detailed technical report on internal validation testing, which precedes formal pre-validation, is most closely related to the scope of an Audit Report/Information (AR) if interpreted broadly as internal validation results, or potentially a Regulatory Filing (RNS) if it's a mandatory disclosure of R&D progress. However, the depth of technical results suggests it is the report itself, not just an announcement of one. Since it is not a full annual report (10-K) or a quarterly report (IR), and it details internal testing/verification, it most closely resembles the scope of an 'Audit Report / Information' (AR) which covers applied accounting principles and results of internal or regulatory stress tests, which can be extended to internal technical validation results in a biotech context, or potentially an Investor Presentation (IP) if it were structured as a presentation. Given the detailed technical validation data, 'AR' is the closest fit among the specific options for reporting on internal verification results, although 'IP' or 'RNS' are possibilities if this is a required disclosure. I will classify it as AR based on the nature of reporting internal verification/testing results.
2019-08-02 Polish
Wyrażenie przez AstraZeneca Pharma Poland sp. z o.o. zainteresowania wsparciem procesu rozwoju systemu BacterOMIC - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board ('Zarząd Scope Fluidics S.A.') informing the public about receiving a non-binding letter ('List') from AstraZeneca Poland expressing interest in supporting the development of the BacterOMIC system. This communication details potential future collaboration, strategic interest from a major pharmaceutical player, and clarifies that the letter is non-binding. This type of announcement, concerning strategic interest, potential partnerships, or significant business developments that are not standard financial reports (10-K, IR, ER) or mandatory regulatory filings (like insider trades or capital changes), fits best under a general regulatory announcement or a specific category related to business development/strategy. Since it is not a merger/takeover (TAR), a financing activity (CAP), or a legal proceeding (LTR), and it is a formal communication to the market about a significant business development, it is classified as a general Regulatory Filing (RNS) as it serves as a mandatory disclosure of material, non-standard information. The document length is short (2706 chars), but it is the primary disclosure itself, not an announcement *of* another report.
2019-07-30 Polish
Rekomendacja projektu rozwijanego przez Bacteromic sp. o.o., spółkę zależną Scope Fluidics S.A., do dofinansowania w ramach programu Horyzont 2020 - SME Instrument - Content (PL)
Regulatory Filings Classification · 1% confidence The document text describes that a subsidiary of the issuer (Scope Fluidics S.A.) has received a positive verification from the European Commission for funding under the Horizon 2020 - SME Instrument; Phase 2 program. It details the potential grant amount (1.927 million EUR) and the purpose (R&D, validation, commercialization). This announcement concerns securing financing/funding for a project, which aligns best with the 'Capital/Financing Update' category, as it relates to securing significant external capital/funding for operations. It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a general Regulatory Filing (RNS). It is a specific announcement about securing funding, making 'CAP' the most appropriate classification.
2019-07-25 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.